论文部分内容阅读
First-line randomized phase Ⅱ study of gemcitabine/cisplatin plus apatorsen or placebo in patients w
【作 者】
：
【机 构】
：
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
【出 处】
：
2015年临床肿瘤学新进展学术研讨会
【发表日期】
：
2015年3期
其他文献
会议
Results of a first-in-human, phase Ⅰ/Ⅱ trial of ASP2215, a selective, potent inhibitor of FLT3/Axl i
会议
Results of the PERSIST-1 phase Ⅲ study of pacritinib (PAC) versus best available therapy (BAT) in pr
会议
Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal
会议
Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG 8040
会议
Phase Ⅲ, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus
会议
Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer
会议
会议